Home Tags Antibody-drug

Tag: Antibody-drug

Dual-Warhead Takes Antibody Drug Conjugates a Step Further

Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing a cell-free protein synthesis technology, presented the first scientific data involving...
CPhl worldwide

CPhI Report Sees ADCs as a Key Driver of Tomorrow’s Healthcare

In the first section of the 2013 annual report and industry expert panel, analysts at CPhI Worldwide and CPhI Pharma Evolution describe how they expect that antibody-drug conjugates or ADCs will become a major product group within the oncology market.

AMF-1c-120 Targets and Binds to Tumors in a Very Localized and...

Results of recent pre-clinical studies with AMF-1c-120 (Amorfix Life Sciences, Ltd) shows that this proprietary anti-ovarian cancer antibody, when administered to live animals, targets and binds to tumors in a very localized and concentrated manner. This is a significant finding because it shows that the antibody retains its tumor-specific binding in vivo.

ADC Therapeutics and Genmab Agree to Develop Antibody-drug Conjugate

Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody...

Women with Highest Expression of Target Protein Benefited Most of Experimental...

The antibody-drug conjugate DMUC5754A, a novel trial drug of a relatively new class of agents developed by Genentech, a member of the Roche Group,...

Second Generation HER2-antibody-drug conjugate Offers Best-in-Class Potential and Improved Therapeutic Index

In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported...

New CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Anti-tumor Activity in...

Preclinical data from SGN-CD33A (Seattle Genetics, Inc), a novel CD33-directed antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML) presented at...

The Next Advancements in Cancer Drug Development: Antibody-Drug Conjugates

The annual meeting of the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL offered a wealth of new...

Linker Stability Enhances Efficacy of Antibody-SN-38

Results from ongoing studies of two bispecific, hexavalent, antibodies, 1R-(E1)-(E1) and 1R-(15)-(15), for treating breast, pancreatic and other solid cancers, were presented during a...

Antibody-drug Conjugate for MBC Highlights Importance of Personalised Approach to Cancer...

Results of the first randomized phase II study, known as TDM4450g, in patients with previously untreated HER2-positive metastatic breast cancer (mBC) were presented today at...

FEATURED RESOURCES